A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo de conferência |
Idioma: | spa |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/46695 |
Resumo: | Os autores externos submeteram sua publicação para apresentação de trabalho no evento “International Symposium on Immunobiologicals”, que foi coordenado e organizado pelo Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), da Fundação Oswaldo Cruz. |
id |
CRUZ_15cf1543096a5e8beafe414fdeee1fc4 |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/46695 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Santos, Eliane Matos dosCamacho, Luiz Antonio BastosLucy, ClaraBrum, Ricardo CristianoXavier, Janaina ReisConceição, Deborah Araújo daOliveira, Patrícia Mouta Nunes deMaia, Maria de Lourdes de SousaPetraglia, TaniaLuz, Kleber2021-04-14T17:47:26Z2021-04-14T17:47:26Z2021SANTOS, E. M. et al. A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos. In: INTERNATIONAL SYMPOSIUM ON IMMUNOBIOLOGICAL, 5., 2021. Rio de Janeiro. Annals... Rio de Janeiro: Bio-Manguinhos, 2021. p. 98.https://www.arca.fiocruz.br/handle/icict/4669510.35259/isi.2021_46695Os autores externos submeteram sua publicação para apresentação de trabalho no evento “International Symposium on Immunobiologicals”, que foi coordenado e organizado pelo Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), da Fundação Oswaldo Cruz.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sérgio Arouca. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Secretaria Municipal de Saúde do Rio de Janeiro. Rio de Janeiro, RJ, Brasil.Centro de Pesquisas Clinicas. São Paulo, SP, Brasil.spaFiocruz/Instituto de Tecnologia em ImunobiológicosSarampoRubéolaVacinaISIMeaslesRubellaVaccineInternational Symposium on ImmunobiologicalsSarampoRubéola (Sarampo Alemão)VacinasA phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhosinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83108https://www.arca.fiocruz.br/bitstream/icict/46695/1/license.txt155f7d692661a91111cc666068bcb611MD51ORIGINALVAC_04.pdfVAC_04.pdfapplication/pdf201882https://www.arca.fiocruz.br/bitstream/icict/46695/2/VAC_04.pdfd6a9c4948405a722cef6c08c0e0ca1a9MD52TEXTVAC_04.pdf.txtVAC_04.pdf.txtExtracted texttext/plain3336https://www.arca.fiocruz.br/bitstream/icict/46695/3/VAC_04.pdf.txt519b7d8fe926aec862a3f754d0567918MD53icict/466952023-04-26 16:57:17.374oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-04-26T19:57:17Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos |
title |
A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos |
spellingShingle |
A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos Santos, Eliane Matos dos Sarampo Rubéola Vacina ISI Measles Rubella Vaccine International Symposium on Immunobiologicals Sarampo Rubéola (Sarampo Alemão) Vacinas |
title_short |
A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos |
title_full |
A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos |
title_fullStr |
A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos |
title_full_unstemmed |
A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos |
title_sort |
A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos |
author |
Santos, Eliane Matos dos |
author_facet |
Santos, Eliane Matos dos Camacho, Luiz Antonio Bastos Lucy, Clara Brum, Ricardo Cristiano Xavier, Janaina Reis Conceição, Deborah Araújo da Oliveira, Patrícia Mouta Nunes de Maia, Maria de Lourdes de Sousa Petraglia, Tania Luz, Kleber |
author_role |
author |
author2 |
Camacho, Luiz Antonio Bastos Lucy, Clara Brum, Ricardo Cristiano Xavier, Janaina Reis Conceição, Deborah Araújo da Oliveira, Patrícia Mouta Nunes de Maia, Maria de Lourdes de Sousa Petraglia, Tania Luz, Kleber |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Santos, Eliane Matos dos Camacho, Luiz Antonio Bastos Lucy, Clara Brum, Ricardo Cristiano Xavier, Janaina Reis Conceição, Deborah Araújo da Oliveira, Patrícia Mouta Nunes de Maia, Maria de Lourdes de Sousa Petraglia, Tania Luz, Kleber |
dc.subject.other.pt_BR.fl_str_mv |
Sarampo Rubéola Vacina ISI |
topic |
Sarampo Rubéola Vacina ISI Measles Rubella Vaccine International Symposium on Immunobiologicals Sarampo Rubéola (Sarampo Alemão) Vacinas |
dc.subject.en.pt_BR.fl_str_mv |
Measles Rubella Vaccine International Symposium on Immunobiologicals |
dc.subject.decs.pt_BR.fl_str_mv |
Sarampo Rubéola (Sarampo Alemão) Vacinas |
description |
Os autores externos submeteram sua publicação para apresentação de trabalho no evento “International Symposium on Immunobiologicals”, que foi coordenado e organizado pelo Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), da Fundação Oswaldo Cruz. |
publishDate |
2021 |
dc.date.accessioned.fl_str_mv |
2021-04-14T17:47:26Z |
dc.date.available.fl_str_mv |
2021-04-14T17:47:26Z |
dc.date.issued.fl_str_mv |
2021 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/conferenceObject |
format |
conferenceObject |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
SANTOS, E. M. et al. A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos. In: INTERNATIONAL SYMPOSIUM ON IMMUNOBIOLOGICAL, 5., 2021. Rio de Janeiro. Annals... Rio de Janeiro: Bio-Manguinhos, 2021. p. 98. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/46695 |
dc.identifier.doi.none.fl_str_mv |
10.35259/isi.2021_46695 |
identifier_str_mv |
SANTOS, E. M. et al. A phase II, III clinical trial to assess immunogenicity, reactogenicity and safety of the measles, rubella vaccine, produced by Bio-Manguinhos. In: INTERNATIONAL SYMPOSIUM ON IMMUNOBIOLOGICAL, 5., 2021. Rio de Janeiro. Annals... Rio de Janeiro: Bio-Manguinhos, 2021. p. 98. 10.35259/isi.2021_46695 |
url |
https://www.arca.fiocruz.br/handle/icict/46695 |
dc.language.iso.fl_str_mv |
spa |
language |
spa |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Fiocruz/Instituto de Tecnologia em Imunobiológicos |
publisher.none.fl_str_mv |
Fiocruz/Instituto de Tecnologia em Imunobiológicos |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/46695/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/46695/2/VAC_04.pdf https://www.arca.fiocruz.br/bitstream/icict/46695/3/VAC_04.pdf.txt |
bitstream.checksum.fl_str_mv |
155f7d692661a91111cc666068bcb611 d6a9c4948405a722cef6c08c0e0ca1a9 519b7d8fe926aec862a3f754d0567918 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813009186901983232 |